Table 1 Clinical characteristics of high- and low- risk groups according to median values of MAPS and MAOS in the TCGA COAD dataset
| Â | MAPS | P* | MAOS | P | ||
|---|---|---|---|---|---|---|
High-risk n (%) | Low-risk n (%) | High-risk n (%) | Low-risk n (%) | |||
n | 220 | 216 | Â | 219 | 217 | Â |
Microsatellite (%) | Â | Â | 0.01 | Â | Â | 0.008 |
 MSI-H | 26 (11.8) | 52 (24.1) |  | 26 (11.9) | 52 (24.0) |  |
 MSI-L | 39 (17.7) | 34 (15.7) |  | 36 (16.4) | 37 (17.1) |  |
 MSS | 150 (68.2) | 127 (58.8) |  | 153 (69.9) | 124 (57.1) | |
Gender = male (%) | 118 (53.6) | 112 (51.9) | 0.782 | 116 (53.0) | 114 (52.5) | 1 |
T (%) | Â | Â | 0.011 | Â | Â | 0.005 |
 T1 | 3 (1.4) | 7 (3.2) |  | 3 (1.4) | 7 (3.2) |  |
 T2 | 30 (13.6) | 44 (20.4) |  | 27 (12.3) | 47 (21.7) |  |
 T3 | 151 (68.6) | 148 (68.5) |  | 154 (70.3) | 145 (66.8) | |
 T4 | 36 (16.4) | 17 (7.9) |  | 35 (16.0) | 18 (8.3) |  |
N (%) |  |  | < 0.001 |  |  | < 0.001 |
 N0 | 104 (47.3) | 151 (69.9) |  | 100 (45.7) | 155 (71.4) | |
 N1 | 57 (25.9) | 44 (20.4) |  | 56 (25.6) | 45 (20.7) |  |
 N2 | 59 (26.8) | 21 (9.7) |  | 63 (28.8) | 17 (7.8) |  |
M (%) |  |  | < 0.001 |  |  | 0.022 |
 M0 | 147 (66.8) | 180 (83.3) |  | 154 (70.3) | 173 (79.7) | |
 M1 | 47 (21.4) | 16 (7.4) |  | 43 (19.6) | 20 (9.2) |  |
 MX | 22 (10.0) | 20 (9.3) |  | 20 (9.1) | 22 (10.1) |  |
Stage (%) |  |  | < 0.001 |  |  | < 0.001 |
 Stage I | 28 (12.7) | 46 (21.3) |  | 26 (11.9) | 48 (22.1) |  |
 Stage II | 71 (32.3) | 102 (47.2) |  | 68 (31.1) | 105 (48.4) | |
 Stage III | 74 (33.6) | 52 (24.1) |  | 82 (37.4) | 44 (20.3) |  |
 Stage IV | 47 (21.4) | 16 (7.4) |  | 43 (19.6) | 20 (9.2) |  |
LVI (%) | Â | Â | 0.105 | Â | Â | 0.001 |
 No | 108 (49.1) | 127 (58.8) |  | 98 (44.7) | 137 (63.1) | |
 Yes | 92 (41.8) | 70 (32.4) |  | 98 (44.7) | 64 (29.5) |  |